Related Experiment Videos
[Winuron - alternative single-dose therapy of gonorrhea]
Zeitschrift Fur Hautkrankheiten
|August 15, 1983
Summary
A single 300 mg oral dose of rosoxacin (Winuron) effectively treated gonorrhea in 97.4% of patients. This antibiotic demonstrated good tolerability and rapid symptom relief, offering a valuable alternative to penicillin.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Gonorrhea remains a significant public health concern, necessitating effective and well-tolerated treatment options.
- Penicillin has been a traditional treatment, but concerns about resistance and side effects warrant exploration of alternatives.
Purpose of the Study:
- To evaluate the efficacy and tolerability of rosoxacin (Winuron) as a single oral dose for treating gonorrhea.
- To compare rosoxacin's effectiveness against Neisseria gonorrhoeae with existing therapies.
Main Methods:
- An open clinical trial involving 152 ambulatory patients diagnosed with gonorrhea.
- Administration of a single 300 mg oral dose of rosoxacin.
- Follow-up examinations to assess cure rates, symptom resolution, and side effects.
Main Results:
- A cure rate of 97.4% was achieved, with only 4 cases of persistent Neisseria gonorrhoeae infection.
- Clinical symptoms subsided in 84.1% of patients within 3 days of treatment.
- Rosoxacin was well-tolerated, with mild and transient side effects reported in 14.5% of patients.
Conclusions:
- A single 300 mg oral dose of rosoxacin demonstrates high efficacy and good tolerability for gonorrhea treatment.
- The rapid symptom relief and favorable safety profile position rosoxacin as a promising alternative to penicillin.
- Further research may explore its role in combating antibiotic resistance in gonorrhea.